CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
$95.30M
Dr. Sean A. McCarthy D.Phil., DPHIL
174.00
South San Francisco, CA
Oct 08, 2015
8.13
$0.15
0.30
1.00
10.79%
9.27%
9.26
0.33
-3.29
0.79
1.00
6.96%
-27.44%
Similar stocks (5)
Nuvation Bio Inc.
NUVB
Instil Bio, Inc.
TIL
Assembly Biosciences, Inc.
ASMB
Spero Therapeutics, Inc.
SPRO
NextCure, Inc.
NXTC
ETF Exposure (13)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.366%
Vanguard Strategic Small-Cap Equity Fund Investor Shares
VSTCX
0.04%
iShares Micro-Cap ETF
IWC
0.02116%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (5)
Nuvation Bio Inc.
NUVB
Instil Bio, Inc.
TIL
Assembly Biosciences, Inc.
ASMB
Spero Therapeutics, Inc.
SPRO
NextCure, Inc.
NXTC
ETF Exposure (13)
Invesco NASDAQ Future Gen 200 ETF
QQQS
0.366%
Vanguard Strategic Small-Cap Equity Fund Investor Shares
VSTCX
0.04%
iShares Micro-Cap ETF
IWC
0.02116%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Extended Market Index Fund
VXF
0%